VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Western equine encephalomyelitis virus PE2/E1 mutant vaccine Western equine encephalomyelitis virus PE2/E2 mutant virus
Vaccine Information Vaccine Information
  • Product Name: WE2130
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Chicken
  • PE2 gene engineering:
    • Type: Gene mutation
    • Description: This PE2/E1 mutant is from Western equine encephalomyelitis virus (Turell et al., 2003).
    • Detailed Gene Information: Click Here.
  • E1 gene engineering:
    • Type: Gene mutation
    • Description: This PE2/E1 mutant is from Western equine encephalomyelitis virus (Turell et al., 2003).
    • Detailed Gene Information: Click Here.
  • Immunization Route: subcutaneous injection
  • Product Name: WE2102
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Chicken
  • PE2 gene engineering:
    • Type: Gene mutation
    • Description: This PE2/E2 mutant is from Western equine encephalomyelitis virus (Turell et al., 2003).
    • Detailed Gene Information: Click Here.
  • E2 gene engineering:
    • Type: Gene mutation
    • Description: This PE2/E2 mutant is from Western equine encephalomyelitis virus (Turell et al., 2003).
    • Detailed Gene Information: Click Here.
  • Immunization Route: subcutaneous injection
Host Response Host Response

Chicken Response

  • Persistence: WE2130 induced low-level viremia in chickens (Turell et al., 2003).
  • Efficacy: WE2130 protected chickens from challenge with wild type WEE two weeks after initial vaccination (Turell et al., 2003).

Chicken Response

  • Persistence: WE2102 induced low-level viremia in chickens (Turell et al., 2003).
  • Efficacy: WE2102 protected chickens from challenge with wild type WEE two weeks after initial vaccination (Turell et al., 2003).
References References
Turell et al., 2003: Turell MJ, O'Guinn ML, Parker MD. Limited potential for mosquito transmission of genetically engineered, live-attenuated western equine encephalitis virus vaccine candidates. The American journal of tropical medicine and hygiene. 2003; 68(2); 218-221. [PubMed: 12641414].
Turell et al., 2003: Turell MJ, O'Guinn ML, Parker MD. Limited potential for mosquito transmission of genetically engineered, live-attenuated western equine encephalitis virus vaccine candidates. The American journal of tropical medicine and hygiene. 2003; 68(2); 218-221. [PubMed: 12641414].